Table 5.

Comparison of DMARD use, according to geographic distance from the closest rheumatology site in 2015.

	Intermediate vs Near				Far vs Near
	Unadjusted		Adjusted^†		Unadjusted		Adjusted^†
	^{^}RR/MR/MD	95% CI	^{^}RR/MR/MD	95% CI	^{^}RR/MR/MD	95% CI	^{^}RR/MR/MD	95% CI
All veterans with IA
No. veterans with ≥ 1 sDMARD	1.10	0.93–1.07	1.01	0.94–1.08	1.11^*	1.01–1.21	1.13^*	1.03–1.24
No. sDMARD in veterans exposed to sDMARD	0.99	0.92–1.06	0.99	0.93–1.06	0.99	0.90–1.08	1.00	0.91–1.10
PDC in veterans exposed to sDMARD	0.01	−0.01 to 0.03	0.00	−0.02 to 0.02	0.02	−0.01 to 0.05	0.01	−0.02 to 0.03
No. veterans with ≥ 1 bDMARD	0.85^*	0.76–0.94	0.88^*	0.79–0.98	0.64^**	0.54–0.76	0.66^**	0.56–0.79
No. bDMARD in veterans exposed to bDMARD	0.99	0.89–1.10	0.99	0.89–1.10	1.02	0.86–1.20	1.02	0.86–1.20
PDC in veterans exposed to bDMARD	0.00	−0.03 to 0.03	0.00	−0.03 to 0.02	0.03	−0.01 to 0.07	0.02	−0.02 to 0.07
Subgroup with ≥ 1 rheumatology visit in 2015
No. veterans with ≥ 1 sDMARD	1.10^*	1.04–1.16	1.10^*	1.04–1.17	1.10	1.00–1.21	1.11^*	1.00–1.22
No. sDMARD in veterans exposed to sDMARD	1.02	0.94–1.11	1.02	0.94–1.11	1.08	0.93–1.24	1.08	0.93–1.24
PDC in veterans exposed to sDMARD	0.01	−0.01 to 0.04	0.01	−0.01 to 0.04	0.04	0.00–0.09	0.03	−0.01 to 0.08
No. veterans with ≥ 1 bDMARD	1.12^*	1.03–1.22	1.12^*	1.03–1.22	0.99	0.84–1.16	0.96	0.82–1.13
No. bDMARD in veterans exposed to bDMARD	0.99	0.88–1.11	0.99	0.88–1.11	1.02	0.83–1.25	1.02	0.83–1.26
PDC in veterans exposed to bDMARD	0.00	−0.03 to 0.03	0.00	−0.03 to 0.03	0.01	−0.04 to 0.07	0.01	−0.04 to 0.07

↵* p < 0.05.
↵** p < 0.001.
↵† Adjusted for age, race, ethnicity, and sex.
↵^ RR (relative risk) used for no. veterans with ≥ 1 rheumatology visit. MR (mean ratio) used for no. provider visits (any specialty) and no. rheumatology visits per veteran. MD (mean difference) used for PDC. sDMARD: synthetic disease-modifying antirheumatic drugs; bDMARD: biologic DMARD; PDC: proportion of days covered; IA: inflammatory arthritis.